Upgrade to SI Premium - Free Trial

RayJay on Veeva (VEEV): 'we haven’t heard any official designation on Bristol-Myers Squib’s plans for CRM going forward, our understanding is that CRM add-ons won’t be portable to Salesforce'

May 23, 2025 1:23 PM
Raymond James analyst Brian Peterson reiterated an Outperform rating and $285.00 price target on Veeva Systems (NYSE: VEEV)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles